

Potential Uses & Benefits/Features and Benefits

- Abdominal body fat reduction
- Enhanced metabolic rate
- Improved fat burning capacity

Formulation

AOD-9604 Acetate 300 mcg Troches

Indications/Dosage

300-350 mcg in the morning for 8-12 weeks (do not swallow)

Mechanism of Action

- Stimulates fat breakdown by inhibiting fat synthesis enzymes, including lipoprotein lipase and acetyl-CoA carboxylase.
- Upregulates beta-3 adrenergic receptor RNA, which plays a role in the breakdown of fatty acids for energy production.

Pharmacokinetics

Distribution: Localized in pancreas, pineal body, thyroid, liver, and kidney cortex.

Metabolism: Rapid degradation via N-terminal truncation.

Excretion: Rapid plasma clearance; no accumulation or long-term retention.

Side Effects

Headache, diarrhea and flatulence (reported from oral administration not oral mucosal administration).

Monitoring

Certain **laboratory values** can suggest underlying hepatocellular stress or injury.

- Liver enzymes: ALT, AST
- Alkaline Phosphatase
- Total Bilirubin
- Albumin


Storage

Room temperature.

Miscellaneous Diagrams

Lipid metabolism in Adipocytes

Process of Making Fat (Lipogenesis) and Breaking Down Fat (Lipolysis)



AC, adenylate cyclase; ACS, acyl-CoA synthase; AKT, AKR mouse thymoma viral proto-oncogene; AR, adrenergic receptor; HSL, hormone sensitive lipase; IR, insulin receptor; PI3K, phosphatidylinositol 3-kinase; PKA, protein kinase A.

References

1. U.S. Food and Drug Administration. Evaluation of AOD-9604-Related Bulk Drug Substances (AOD-9604 (Free Base) and AOD-9604 Acetate) for Inclusion on the 503A Bulk Drug Substances List: FDA Briefing Document for the Pharmacy Compounding Advisory Committee (PCAC) Meeting, December 4, 2024. U.S. Department of Health and Human Services, 4 Dec. 2024, <https://www.fda.gov/media/183584/download>.
2. Stier, Heike, Evert Vos, and David Kenley. "Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans." *Journal of Endocrinology and Metabolism*, vol. 3, no. 1–2, Apr. 2013, pp. 7–15. Elmer Press, doi: 10.4021/jem157w. Accessed 18 Aug. 2025.
3. Moré, Margret I., and David Kenley. "Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health." *Journal of Endocrinology and Metabolism*, vol. 4, no. 3, June 2014, pp. 64–77. Elmer Press, <https://jofem.org/index.php/jofem/article/view/213>. Accessed 18 Aug. 2025.
4. Saponaro, Chiara, et al. "The Subtle Balance between Lipolysis and Lipogenesis: A Critical Point in Metabolic Homeostasis." *Nutrients*, vol. 7, no. 11, 2015, pp. 9453–9474. MDPI, <https://doi.org/10.3390/nu7115475>. Accessed 18 Aug. 2025.